Ernexa Therapeutics (ERNAW) Return on Capital Employed (2011 - 2026)

Ernexa Therapeutics has reported Return on Capital Employed for 16 years, with the latest figure at 257.38% in Q1 2026.

• For the quarter ending Q1 2026, Return on Capital Employed fell 49661.0% year-over-year to 257.38%; the trailing twelve-month figure through Mar 2026 stood at 257.38% (down 49661.0% YoY), and the FY2025 full-year result was 382.16%, down 31756.0% from the prior year.
• Return on Capital Employed for Q1 2026 stood at 257.38%, up from 322.42% in the prior quarter.
• The five-year high for Return on Capital Employed was 239.23% in Q1 2025, with the low at 478.64% in Q2 2022.
• Historically, Return on Capital Employed has averaged 190.51% across 5 years, with a median of 224.98% in 2022.
• Annual changes were most pronounced in 2023 — Return on Capital Employed surged 38266 bps — and 2026, when it tumbled 49661 bps.
• Ernexa Therapeutics' Return on Capital Employed stood at 238.14% in 2022, then surged by 80 bps to 47.91% in 2023, then tumbled by 820 bps to 440.84% in 2024, then climbed by 27 bps to 322.42% in 2025, then gained by 20 bps to 257.38% in 2026.
• The last three Return on Capital Employed figures came in at 257.38% (Q1 2026), 322.42% (Q4 2025), and 209.57% (Q3 2025), per Business Quant data.